Inactive Instrument
Company Checkmate Pharmaceuticals, Inc.
Stocks
CMPI
US1628181083
Biotechnology & Medical Research
Business description: Checkmate Pharmaceuticals, Inc.
Number of employees: 31
Sales by Activity: Checkmate Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) |
|---|
Geographical breakdown of sales: Checkmate Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) |
|---|
Executive Committee: Checkmate Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 2018-12-11 | |
Robert Landry
DFI | Director of Finance/CFO | 62 | 2022-05-30 |
James Wooldridge
CTO | Chief Tech/Sci/R&D Officer | 60 | 2019-09-30 |
Chris French
CTO | Chief Tech/Sci/R&D Officer | - | 2016-06-30 |
Nouhad Husseini
PRN | Corporate Officer/Principal | - | 2022-05-30 |
Composition of the Board of Directors: Checkmate Pharmaceuticals, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Nouhad Husseini
BRD | Director/Board Member | - | 2022-05-30 |
Company details: Checkmate Pharmaceuticals, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.10% | -8.35% | +38.48% | +66.99% | 66.22B | |
| -0.41% | +4.99% | +7.61% | +72.82% | 55.2B | |
| +0.74% | +7.31% | +12.50% | +88.71% | 52.79B | |
| +0.61% | +6.22% | +27.28% | +50.97% | 45.53B | |
| -1.08% | +8.76% | +21.07% | +131.38% | 43.94B | |
| -3.39% | -3.01% | +250.89% | +571.04% | 41.64B | |
| -1.67% | +8.06% | +14.17% | +56.67% | 34B | |
| -8.38% | -9.01% | +25.65% | -1.82% | 25.84B | |
| +1.30% | +6.97% | +38.37% | +28.59% | 23.51B | |
| Average | -1.82% | +3.43% | +48.45% | +118.37% | 43.19B | |
| Weighted average by Cap. | -1.69% | +3.43% | +47.06% | +122.37% |
